Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• In patients with exocrine pancreatic insufficiency (EPI), including those with chronic pancreatitis, pancrelipase (Creon®) was associated with increased coefficient of fat absorption (CFA) levels, showing an improvement range from a 7.5% increase in placebo recipients to a 36% increase in those treated with Creon®.
• Pancrelipase, including Creon®, also improved the coefficient of nitrogen absorption (CNA) in EPI patients compared to placebo, with no significant differences in CNA-72h observed between Creon® (82.0% [standard error (SE): 1.2]) and Zenpep® (80.9% [SE: 1.2]) in a head-to-head study.
• Treatment with pancreatic enzyme replacement therapy (PERT) generally led to increases in body weight (0.1 to 6.1 kg) and body mass index (BMI) or reduced their decline, benefiting EPI patients with weight loss or low BMI.
• PERT, including Creon®, was generally reported as safe and well-tolerated across 18 studies, with no specific safety concerns or adverse effects highlighted for particular population types or subgroups.
• The systematic review focused on patients with EPI due to conditions like cystic fibrosis and chronic pancreatitis, finding that treatment with Creon® significantly improved the CFA and CNA, as well as body weight and BMI, which is particularly relevant for EPI patients experiencing malabsorption and weight loss.